Pharma Marketing Network

Back in September, I noted that Pharma PAC contributions to Obama was growing faster than contributions to Obama (contributions to Obama grew by 6.1%...

"You don't tug on Superman's cape," says Jim Croce, and you don't mess around with Pfizer! That's a lesson some guys from West Babylon,...

Pfizer recently decided to abandon its efforts to develop medicines for heart disease and focus instead on more-profitable areas, such as cancer and Alzheimer's...

First it was direct-to-consumer (DTC) advertising, then free gifts to physicians, followed by pharma-funded continuing medical education (CME). Now the distribution of free Rx...

Bob Ehrlich, Chairman of DTC Perspectives, admitted today in his e-mail OpEd piece that "It looks increasingly likely we will have a Democratic victory...

I am beginning to believe that in countries like the UK, where direct-to-consumer (DTC) advertising is not permitted, pharmaceutical companies have used the bundles...

By the time the FDA issues a warning letter about a DTC ad that violates FDA regulations -- as it did on September 25,...

Healthcare marketers are rewarded for increasing product revenue. However, product managers often miss a golden opportunity to drive product sales: they neglect to communicate clinical trial results properly and consequently fail to capitalize on completed medical research.This article highlights how to effectively communicate scientific evidence in order to realize the full medical and commercial value of your brand and to maximize sales.

Continuing Medical Education (CME) in Europe has undergone some major shifts in recent years. These have varied across Europe: from national changes in which systems have moved from being voluntary to mandatory, to the establishment of more formal systems to guide physicians on how to keep up-to-date with latest clinical practice. This article, written two European CME consultants, provides an overview of the state of CME in the UK, France, and other European countries.

This year is proving to be a critical one for many industries, including the pharma-ceutical industry. Actionable, evidence-based and global pharmaceutical competitive intelligence (CI) and general business intelligence (BI) will play an important role in the drama about to unfold. This article highlights several presentations made at the 2008 Pharmaceutical Competitive Intelligence Conference and discusses some common themes, including how environments for the pharmaceutical and device industries are changing dramatically with implications for CI going forward, the importance of keeping an eye on China, and whether CI is a strategic or tactical discipline.